What's Happening?
Daiichi Sankyo and AstraZeneca have announced promising results from a sub-study of the TROPION-PanTumor03 phase 2 trial, which evaluated the combination of DATROWAY (datopotamab deruxtecan) and rilvegostomig in patients with locally advanced or metastatic
urothelial cancer. The trial demonstrated a confirmed objective response rate of 68.2% and a disease control rate of 95.5% in first-line treatment settings for patients ineligible for cisplatin. The study also showed a 38.9% response rate in second-line settings for patients previously treated with platinum-based chemotherapy. These findings were presented at the 2025 European Society for Medical Oncology Congress.
Why It's Important?
The results of this trial are significant as they offer new hope for patients with metastatic urothelial cancer, a condition with limited treatment options and a low five-year survival rate. The high response and disease control rates suggest that DATROWAY plus rilvegostomig could become a viable treatment option, potentially improving outcomes for patients who have exhausted other therapies. This development could influence future treatment protocols and encourage further research into combination therapies for difficult-to-treat cancers.
What's Next?
Following these promising results, Daiichi Sankyo has initiated the TROPION-Urothelial03 phase 2/3 trial to further evaluate DATROWAY in combination with platinum-based chemotherapy. This trial will compare the efficacy of DATROWAY with standard chemotherapy regimens in patients with metastatic urothelial carcinoma. The outcomes of this trial could lead to new standard-of-care treatments and potentially improve survival rates for patients with this aggressive cancer.
